There were significant differences (P < 0.05) among the three groups in terms of duration of diabetes, previous PCI, previous stroke, BMI, SBP, DBP, HR, GRACE score, multi-vessel disease, treatment strategy, FBG, HbA1c, HDL-C, Uric acid, NT-proBNP, eGFR and the use of medications at discharge including clopidogrel or ticagrelor, β-blocker, angiotensin-converting enzyme inhibitor (ACE-I) or angiotensin II receptor blocker (ARB) and insulin, and no significant difference was found in the other indicators. This evidence concerns the gene NPPB and Stroke.